But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.Johnson & Johnson, Vaccination and Immunization, Coronavirus (2019-nCoV), Food and Drug Administration, Centers for Disease Control and Prevention, Moderna Inc, Pfizer Inc, Regulation and Deregulation of IndustryRead More
